Latest topics page 47
Topics ordered by most recent activity across all 71 subcategories.
1,535 topics · page 47 of 52
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…
|
+15 | 19 | 22k | 18mo |
|
SURPASS-2 and the comparator dose question that will not go away
SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…
|
+101 | 111 | 1.5k | 18mo |
|
Sample size intuition for a personal experiment
On the subject in the title: Sample size intuition for a personal experiment Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is…
|
4 | 62k | 18mo | |
|
Coming back to: Preparing for an appointment: one page, three questions
Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. General question, not a request for advice about my own care — I…
|
+139 | 151 | 47k | 18mo |
|
[2026 update] New subcategory: rationale and scope
New subcategory: rationale and scope — setting out what I have, and where I think it stops being reliable. Nominating something for promotion into the documentation commons. The topic in question keeps being…
|
+142 | 163 | 1.8k | 18mo |
|
Fixed versus detachable needles: the trade-offs
Posting this under the heading it deserves: Fixed versus detachable needles: the trade-offs Everything below is what sits behind that. I have read the maintained page on this and I still have a gap, so I am…
|
+117 | 121 | 7.3k | 18mo |
|
Isotonicity and what happens when you get it wrong
On the subject in the title: Isotonicity and what happens when you get it wrong Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise be.…
|
+27 | 31 | 11k | 18mo |
|
What a well-designed human trial of a secretagogue would look like
What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…
|
2 | 7.2k | 18mo | |
|
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold?
The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing…
|
+15 | 19 | 930 | 18mo |
|
Turnaround times and what they mean for a decision — one year on
On the subject in the title: Turnaround times and what they mean for a decision — one year on Working notes rather than a conclusion. Structured report rather than an opinion, following the format the…
|
+25 | 29 | 22k | 18mo |
|
Follow-up: What this community means by "a source", in practical terms
The question in the title: What this community means by "a source", in practical terms I will give what I have already checked below so nobody repeats it. I want to check my reasoning rather than get a…
|
+16 | 20 | 7k | 18mo |
|
Coming back to: Grapefruit: why this class is not the class that cares
Posting this under the heading it deserves: Grapefruit: why this class is not the class that cares Everything below is what sits behind that. I have read the maintained page on this and I still have a gap, so…
|
+44 | 48 | 12k | 18mo |
|
[2026 update] Step therapy requirements and how to satisfy them
Step therapy requirements and how to satisfy them Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+111 | 122 | 3.4k | 18mo |
|
Swirling versus inverting versus leaving it alone
On the subject in the title: Swirling versus inverting versus leaving it alone Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 18k | 18mo | |
|
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…
|
+48 | 52 | 59k | 18mo |
|
Recovery when intake is low: what to cut first
Recovery when intake is low: what to cut first Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a number without a method…
|
+85 | 91 | 1.2k | 18mo |
|
Follow-up: Oral contraceptives and delayed emptying: what the data shows
Oral contraceptives and delayed emptying: what the data shows — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern is…
|
+31 | 35 | 13k | 18mo |
|
Follow-up: Dead volume across syringe and needle combinations
Dead volume across syringe and needle combinations — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how quickly these go…
|
+81 | 98 | 22k | 18mo |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still…
|
+131 | 147 | 47k | 18mo |
|
Follow-up: Individual participant data versus aggregate data
Individual participant data versus aggregate data — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURPASS-4 ( Lancet , 2021) and finding the…
|
+101 | 111 | 23k | 18mo |
|
Second pass at: Transit times by route, from a logged dataset
On the subject in the title: Second pass at: Transit times by route, from a logged dataset Working notes rather than a conclusion. A logistics question, since the answers here are usually better than anywhere…
|
2 | 59k | 19mo | |
|
Books and papers worth reading that are not about this at all
On the subject in the title: Books and papers worth reading that are not about this at all Working notes rather than a conclusion. Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
|
+13 | 17 | 13k | 19mo |
|
Follow-up: Tirzepatide's shorter half-life and its one practical consequence
Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of…
|
+130 | 137 | 11k | 19mo |
|
What a stability-indicating method is and how you demonstrate one — one year on
What a stability-indicating method is and how you demonstrate one — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. A documentation question rather than…
|
+100 | 112 | 15k | 19mo |
|
Drawing from a pen cartridge with a syringe: how the risk profile changes
Posting this under the heading it deserves: Drawing from a pen cartridge with a syringe: how the risk profile changes Everything below is what sits behind that. I have read the maintained page on this and I…
|
2 | 159 | 19mo | |
|
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…
|
2 | 54k | 19mo | |
|
Hello from a laboratory that does not do peptides — does this still hold?
Asking directly, because I could not find a straight answer: Hello from a laboratory that does not do peptides — does this still hold? Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
|
+1 | 5 | 35k | 19mo |
|
Follow-up: Reporting a discrepancy without making an allegation
Reporting a discrepancy without making an allegation Writing it up because I had to work it out twice and would rather nobody else did. Structured report rather than an opinion, following the format the…
|
2 | 24k | 19mo | |
|
Coming back to: Cost per delivered dose, which is the number that matters
On the subject in the title: Cost per delivered dose, which is the number that matters Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
+6 | 10 | 2.5k | 19mo |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…
|
+72 | 77 | 7.2k | 19mo |